Pharmaceutical

Jazz Pharma’s Enrylaze wins European approval for AML and LBL

The European Commission has approved Enrylaze for treating acute lymphoblastic leukaemia and lymphoblastic lymphoma.

Sep 23, 2023 - 20:00
Jazz Pharma’s Enrylaze wins European approval for AML and LBL
The European Commission has approved Enrylaze for treating acute lymphoblastic leukaemia and lymphoblastic lymphoma.
Read the original article

Tags:

Previous Article

FDA clears Krystal Biotech’s IND for Type 1 AATD treatment KB408

Next Article

Over half of world’s population not covered by essential healthcare services

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: The next Census could undercount the number of disabled Americans by 20 million

Opinion: The next Census could undercount the number of...

Nov 27, 2023

STAT+: DOJ, FTC primed for more aggressive scrutiny of health care mergers

STAT+: DOJ, FTC primed for more aggressive scrutiny of ...

Jul 20, 2023

Absci and Caltech receive grant to develop HIV therapeutic vaccine

Absci and Caltech receive grant to develop HIV therapeu...

Aug 12, 2023